Lonza hit by lower demand last year; cuts capex in 2010
Full-year income at the Lonza was hit by falling demand for life science ingredients and custom manufacturing services and only modest gains for its bioscience unit.
Full-year income at the Lonza was hit by falling demand for life science ingredients and custom manufacturing services and only modest gains for its bioscience unit.
Biotechnology firm Biocon is in talks with CRO Siro Clinpharm about a potential partnership, according to reports in the Indian media.
Crospon has spun out its transdermal controlled release patch into a distinct company, two years after it licensed the system from HP, using funding from a pharma firm to further its development.
The global market for RFID products and services in the pharma industry will be worth $884m (€631m) in 2015, according to a report, but apprehensions about initial costs and return-on-investment need to be overcome.